|
|
| Line 1: |
Line 1: |
| ==2012 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (DO NOT EDIT)<ref name="pmid22315257">{{cite journal| author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel| title=Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= 7S-47S | pmid=22315257 | doi=10.1378/chest.1412S3 | pmc=PMC3278060 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315257 }} </ref>==
| | {{Familytree/start}} |
| | | {{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | }} |
| ===Long-term Treatment of Patients With PE (DO NOT EDIT)<ref name="pmid22315257">{{cite journal| author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel| title=Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= 7S-47S | pmid=22315257 | doi=10.1378/chest.1412S3 | pmc=PMC3278060 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315257 }} </ref>===
| | {{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | }} |
| {|class="wikitable" | | {{Family tree | | | | | B01 | | | | | | | | | | | | | | | | | | | }} |
| |- | | {{Family tree | | | | | |!| | | | | | | | | | | | | | | | | | | | }} |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | | {{Family tree | | | | | C01 | | | | | | | | | | | | | | | | | | | }} |
| |- | | {{Family tree |,|-|-|-|-|^|-|-|-|.| | | | | | | | | | | | | | | | }} |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' In patients with PE who are treated with [[VKA]], we recommend a therapeutic [[INR]] range of 2.0 to 3.0 (target INR of 2.5) over a lower (INR < 2) or higher (INR 3.0-5.0) range for all treatment durations. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | {{Family tree | D01 | | | | | | D02 | | | | | | | | | | | | | | | }} |
| |- | | {{Family tree |!| | | | | | | | |`|-|.| | | | | | | | | | | | | | }} |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' In patients with PE and active cancer, if there is a low or moderate bleeding risk, we recommend extended anticoagulant therapy over 3 months of therapy. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | {{Family tree |!| | | | | | | | | | |!| | | | | | | | | | | | | | }} |
| |- | | {{Family tree |!|,|-|-|-|-|-|-| E01 |(| | | | | | | | | | | | | | | | | }} |
| |} | | {{Family tree |!|!| | | | | | | | | |!| | | | | | | | | | | | | }} |
| | | {{Family tree |!|!|,|-|-|-|-|-| F01 |(| | | | | | | | | | | | | | | | | }} |
| {|class="wikitable" | | {{Family tree |!|!|!| | | | | | | | |!| | | | | | | | | | | | | }} |
| |- | | {{Family tree |!|!|!| | |,|-|-| G01 |(| | | | | | | | | | | | | | | | | }} |
| | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class II]] | | {{Family tree |!|!|!| | |!| | | | | |!| | | | | | | | | | | | | }} |
| |- | | {{Family tree |!|!|!| | |!|,|-| H01 |(| | | | | | | | | | | | | | | | | }} |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In patients with PE and active cancer, if there is a high bleeding risk, we suggest extended anticoagulant therapy. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | {{Family tree |!|!|!| | |!|!| | | | |!| | | | | | | | | | | | }} |
| |- | | {{Family tree |!|!|!| | |!|!| | I01 |'| | | | | | | | | | | | | | | | }} |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' In patients with PE and no cancer, we suggest VKA therapy over LMWH for long-term therapy ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: C]])''. For patients with PE and no cancer who are not treated with VKA therapy, we suggest LMWH over dabigatran or rivaroxaban for long-term therapy. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | | {{Family tree |!|!|!| | |!|!| | |!| | | | | | | | | | | | | | }} |
| |- | | {{Family tree | J01 | | J02 | | J03 | | J04 | | J05 | | J06 | }} |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' In patients with PE and cancer, we suggest LMWH over VKA therapy ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''. In patients with PE and cancer who are not treated with LMWH, we suggest VKA over dabigatran or rivaroxaban for long-term therapy ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: C]])''. <nowiki>"</nowiki> | | {{Family tree/end}} |
| |- | |
| |} | |
| | |
| ===Patients Undergoing General, GI, Urological, Gynecologic, Bariatric, Vascular, Plastic, or Reconstructive Surgery (DO NOT EDIT)<ref name="pmid22315257">{{cite journal| author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel| title=Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= 7S-47S | pmid=22315257 | doi=10.1378/chest.1412S3 | pmc=PMC3278060 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315257 }} </ref>===
| |
| {|class="wikitable" | |
| |- | |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |
| |- | |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' For high-VTE-risk patients undergoing abdominal or pelvic [[surgery]] for [[cancer]] who are not otherwise at high risk for major bleeding complications, we recommend extended-duration pharmacologic prophylaxis (4 weeks) with [[LMWH]] over limited-duration prophylaxis. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |
| |- | |
| |} | |
| | |
| ===Patients With Cancer in the Outpatient Setting (DO NOT EDIT)<ref name="pmid22315257">{{cite journal| author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel| title=Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= 7S-47S | pmid=22315257 | doi=10.1378/chest.1412S3 | pmc=PMC3278060 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315257 }} </ref>===
| |
| {|class="wikitable" | |
| |- | |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |
| |- | |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' In outpatients with [[cancer]] who have no additional risk factors for [[VTE]], we recommend against the prophylactic use of VKAs. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |
| |- | |
| |} | |
| | |
| {|class="wikitable" | |
| |- | |
| | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class II]] | |
| |- | |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' In outpatients with cancer who have no additional risk factors for VTE, we suggest against routine prophylaxis with LMWH or LDUH. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |
| |- | |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' In outpatients with solid tumors who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylactic-dose LMWH or LDUH over no prophylaxis. ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |
| |- | |
| |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' In outpatients with cancer and indwelling central venous catheters, we suggest against routine prophylaxis with LMWH or LDUH ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: B]])'' and suggest against the prophylactic use of VKAs ''([[American College of Chest Physicians#Level of Evidence|Level of Evidence: C]])''. <nowiki>"</nowiki> | |
| |- | |
| |} | |